Human protein C (Ceprotin)

Status:

Do Not Prescribe (DNP)

Decision Date:

May 2023

Comments

DNP: Use for prophylaxis and treatment of purpura fulminans, coumarin‑induced skin necrosis and venous thrombotic events in patients with severe congenital protein C deficiency. Await national guidance. (Decision date - May 2023)

search again